Back ICAAC 2010

ICAAC 2010

HIV Positive People May Need Triple Dose of Hepatitis A Vaccine

People with HIV require 3 doses of hepatitis A virus (HAV) vaccine to achieve the same level of antibody protection that HIV negative people can get with 2 doses, according to a study presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last month in Boston. HAV antibody response was particularly weak among HIV positive men with a CD4 count below 200, all of whom needed the third vaccine booster dose.

Read more:

Bone Loss and Low Vitamin D Levels Are Common among People with HIV

Nearly half of HIV positive people taking antiretroviral therapy (ART) in a Spanish study had low bone mineral density, and more than one-quarter experienced progressive bone loss, according to findings presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last month in Boston. Two other studies found that HIV positive people are likely to have low levels of vitamin D, which is crucial for bone health.

HIV Coinfection Does Not Worsen Liver Transplant Outcomes in People with Hepatitis B or C

HIV positive liver transplant recipients with hepatitis B virus (HBV) or hepatitis C virus (HCV) coinfection did not fare worse overall than HIV negative people, according to a Spanish study presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last month in Boston. Coinfected patients were less likely to experience organ rejection, but HCV recurrence was a leading cause of adverse outcomes.

Read more:

Large Meta-analysis Shows HIV Positive Women Respond as Well as Men to Antiretroviral Therapy

Treatment-naive and treatment-experienced women with HIV achieve antiretroviral therapy (ART) outcomes similar to those of men, according to a meta-analysis of more than 40 randomized clinical trials presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last month in Boston. Efficacy of all antiretroviral classes was similar for women and men, but women were less likely to prematurely stop study drugs due to treatment failure.

ICAAC 2010: Experimental Drug LMV-601 Inhibits HPV Replication and Abnormal Cell Growth in Laboratory Study

Lumavita's LMV-601, an investigational PC-PLC inhibitor, reduced expression of high-risk human papillomavirus (HPV) types 16, 18, and 31, and over time improved pre-cancerous cervical cell abnormalities in a laboratory study, researchers reported at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last month in Boston.

alt

Read more: